NCT00917748View on ClinicalTrials.gov

Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Prostatic NeoplasmsBreast Cancer
Interventions
DRUG

DOCETAXEL(XRP6976) + MODAFINIL

arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily

DRUG

Modafinil

best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily

DRUG

Placebo of Modafinil

Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Macquarie Park

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00917748 - Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF) | Biotech Hunter | Biotech Hunter